Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-O rollover study of olaparib in oncology patients with continued clinical benefit
2024-512982-15-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, epithelial ovarian cancer (EOC), breast cancer and 3 more, sponsored by AstraZeneca. Primary endpoint: Safety: SAEs and AESIs. Planned start Aug 2024; status: authorised.
02
Drugs
olaparib
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)breast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-512982-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512982-15-00.